Logo

OpiCalc

FavoritesSpecialtiesDrugsGuidelinesMost Used

All Specialties

OpiCalc Logo
FavoritesSpecialtiesDrugsGuidelinesMost Used
FavesSpecsDrugsGuidesTop
BED Calculator (Biological Effective Dose)DS-GPA Score (Diagnosis-Specific GPA)EQD2 Calculator (Equivalent Dose in 2Gy)GPA Score (Graded Prognostic Assessment)Iso-effective Dose ConverterNSD Calculator (Ellis Formula)RPA Grading for Brain MetastasesRadiation Necrosis MRI IndexSRS Dose Selection (RTOG)TDF Factor (Time-Dose-Fractionation)
OpiCalc Logo

OpiCalc

Easy, fast, and private medical tools for clinicians. Always free.

No Login Required
Ready for the Bedside

Resources

About UsEditorial PolicyMedical DisclaimerPrivacy PolicyTerms of UseCookie Policy

Support

Contact Us

Clinical Notice:OpiCalc is not a substitute for professional clinical judgment. Always verify dosages and guidelines.

OpiCalc © 2018-2026

•

All Rights Reserved

In Recent Clinical News

Scanning Medical Journals

No new significant updates or guidelines matching this topic were found today. We will check again soon.

Radiation Oncology

BED Calculator (Biological Effective Dose)

Radiobiology Core — LQ Model / BED / EQD2

Fractionation Parameters

Neural tissue: 2 Gy · Melanoma/RCC: 2.5–5 Gy · H&N tumour: 10–15 Gy

Formula Reference (Fowler, Br J Radiol, 1989)

BED = D × (1 + d / α/β)

EQD₂ = D × (d + α/β) / (2 + α/β)

EQD₂ = BED / (1 + 2 / α/β)

Ready for Calculation

Enter fractionation parameters or select a common regimen above to calculate BED and EQD2.

BEDBiologically Effective Dose — tissue-weighted total effect
EQD₂Equivalent dose in 2 Gy fractions — directly comparable to standard EBRT outcomes
α/βTissue-specific radiosensitivity ratio — higher = more linear dose response
Guidelines & Evidence

Verified

Last Review: 2026

Radiobiology Background

The Linear-Quadratic (LQ) Model

The BED is derived from the Linear-Quadratic model of cell kill, which posits that ionizing radiation causes lethal DNA damage via two mechanisms: single-hit (α component) and two-hit (β component) events. Proposed by Fowler in 1989, BED provides a tissue-specific common currency for comparing the biological potency of radiation delivered under any combination of total dose, dose per fraction, and number of fractions. It is indispensable for planning dose escalation, hypofractionation (SBRT/SABR), brachytherapy conversions, managing treatment interruptions, and estimating normal tissue complication probability (NTCP) for late-responding organs at risk.

The BED Formula

$$BED = D \times \left(1 + \frac{d}{\alpha/\beta}\right)$$ Where: D = Total Dose (Gy), d = Dose per Fraction (Gy), α/β = Tissue-specific radiosensitivity ratio (Gy). The term in parentheses is the Relative Effectiveness (RE) factor — the biological potency per unit of physical dose relative to infinitely small fractions.

EQD2 — Equivalent Dose in 2 Gy Fractions

$$EQD_2 = D \times \frac{d + (\alpha/\beta)}{2 + (\alpha/\beta)}$$ EQD2 converts any fractionation scheme into the total dose that would produce the same biological effect if delivered in standard 2 Gy fractions. It is directly comparable to historical clinical dose-response data. Relationship: EQD₂ = BED ÷ (1 + 2/α/β). Unlike BED, EQD2 units are directly equivalent to standard Gy doses recorded in the literature.

Alpha/Beta (α/β) Ratios — Critical Reference Values

Tissue / Tumour TypeTypical α/βClinical RationaleKey Sources
Early-responding tissues & most tumours~10 GyRapidly proliferating cells; predominantly α-type cell kill. Small fraction-size advantage; conventional fractionation well-tolerated.Fowler, Br J Radiol, 1989
Late-responding normal tissues (spinal cord, brain, lung, kidney, rectum)~3 GySlowly cycling cells with large capacity for sublethal damage repair. Exquisitely sensitive to dose per fraction — hyperfractionation is protective.Thames & Hendry, 1987; Hall & Giaccia, 2018
Prostate adenocarcinoma1.5 Gy (range 0.8–3.7 Gy)Atypically low α/β, similar to late-responding tissue. Theoretical therapeutic gain from hypofractionation or HDR brachytherapy. Supported by multiple randomised trials (CHHiP, HYPO-RT-PC).Brenner & Hall, IJROBP, 1999; Fowler et al., IJROBP, 2001; Miralbell et al., IJROBP, 2012
Breast cancer~3–4 GyModerate α/β supports moderate hypofractionation. The FAST-Forward trial confirmed 26 Gy in 5 fractions is non-inferior to 40 Gy in 15 fractions.FAST-Forward Trial, Lancet, 2020
Melanoma / Renal Cell Carcinoma (RCC)~2.5–5 GyClassically "radioresistant" at conventional doses; large fractions via SBRT overcome this. RCC α/β may be low, making SBRT biologically advantageous.Bentzen & Joiner, 2009
Head & Neck SCC (tumour)~10–15 GyHigh α/β; rapidly repopulating. Accelerated fractionation or concomitant boost reduces repopulation penalty. Overall treatment time is critical.Withers et al., 1988 (dog-leg curve)
Lung SBRT tumour target~10 Gy (assumed)SBRT doses of 3–5 fractions at 10–20 Gy/fx deliver BED₁₀ of 100–220 Gy. Standard LQ model applicability at >8 Gy/fx is debated.Brown, Carlson & Brenner, IJROBP, 2014

Historical Context: From NSD to BED

Before BED, oncologists used Ellis's Nominal Standard Dose (NSD, 1969) and the Orton-Ellis Time-Dose Factor (TDF, 1973) to compare fractionation schedules. These empirical formulae were later shown to be inadequate, particularly for hypo- and hyperfractionated regimens. In 1989, Fowler proposed the BED formulation in the British Journal of Radiology, deriving it from the LQ model and explicitly incorporating an overall time factor for tumour repopulation. Twenty-one years later, Fowler reviewed its widespread adoption across EBRT, brachytherapy, SRS, SBRT, particle therapy, and radionuclide treatment.

Last Comprehensive Review: 2026